Surrozen

CompanyUnited States

Surrozen develops one asset, in phase 1 (SZN-8141 in diabetic macular edema). Mostly antibody acting on VEGFA and FZD4; based in the United States.

1
Asset
Furthest stage: Phase 1; 0
Trials: 0
Signals

Pipeline

1

SZN-8141
Bifunctional Frizzled 4-mediated Wnt agonist and vascular endothelial growth factor antagonist antibody.
Phase 1, Antibody, VEGFA, FZD4, diabetic macular edema

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms2
Similar companies6